

## **H2020 SC1-BHC-07-2019: Clinical and research related partners sought for a project consortium**

POD Reference [RDDE20181120001](#)

### Summary

A German research institute is preparing a proposal for the H2020 SC1-BHC-07-2019 call. Focus is a biomaterial platform that can be customized for various, engineered tissue types. The aim is to overcome current state of the art constraints in cell sheet engineering. The institute will take the lead and is looking for Health Technology partners and/or for clinical partners (tissue engineering) to join the consortium and to conclude a research cooperation agreement.

### Description

A Research institute from Germany with a strong expertise and history in the field of biomaterials plans to submit a proposal within the H2020 SC1-BHC-07-2019 call. The institute will overtake the role as lead partner. Now they are looking for project partners to join the consortium.

The objective is to develop a biomaterial that is not only able to ensure a healthy cell culturing process but also to extract the engineered tissue without causing any damage by a controlled degradation process.

As a proof of concept, the usefulness of this technique has been demonstrated by creating corneal endothelial lamellae (artificial Descemet membrane endothelial keratoplasty (DMEK) tissue) ex vivo. The project proposal aims to apply this technology to different tissue types other than cornea.

The German Research institute is now looking for cooperation with Health Technology partners and clinical partners, who want to support the idea and are interested in a 3-5 years partnership- 156-260 weeks).

In concrete, they are looking for following partners:

- Partners from clinical research areas (tissue engineering), who would be willing to test and apply the biotechnology platform
- Health Technology partners to support the regulatory issues of the project

The optimal partner should provide complementary expertise in the outlined field, potentially in testing either pharmaceutical or biomedical applicability of the compounds developed. Expertise in EU-projects and expertise of respective content is prerequisite.

**Expressions of Interest are welcome until 31.01.2019**

**Call deadline: 16th April 2019**

### Advantages and Innovations

The project will aim to deliver biotechnology solutions which are suitable for effective regenerative medicine applications as well as to overcome current constraints of the state of the art.

The ultimate goal is to achieve synergies through collaboration between industry and science to advance regenerative medicine towards clinical applications.